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Abstract. Enterobacter sakazakii, a pathogen that can be found in powdered infant milk formula, can cause adverse 
health effects on infants. Using Vickrey auction, this study examines parents’ willingness to pay (WTP) for a quality 
assurance label on powdered infant milk formula. The influence of ambiguity with the incidence rate information and 
provision of safe-handling information on WTP are also evaluated using three experiments/treatments. The mean 
price premium parents are willing to pay for the safer and quality assurance labelled powdered infant milk formula 
ranges from 61 to 133 Eurocents per 100 grams depending on the treatment. While no ambiguity effects are generally 
found,  provision  of  safe-handling  information  has  a  significant  influence  on  WTP.  When  the  safe-handling 
information was given, WTP for the quality assurance label was significantly reduced and ranged from 39 to 69 
Eurocents per 100 grams depending on the treatment. The results suggest that parents significantly value a quality 
assurance label with or without clear incidence rate information. Parents’ valuation of the label, however, is reduced 
with the provision of safe-handling information. 
 






Many producers offer a wide range of powdered infant milk formula in the market to satisfy the 
nutritional needs of infants and newborns that are not breast-fed. These infant milk formulas, however, 
are not sterile. They can contain, in low doses,  microorganisms that can cause severe illnesses. The 
microorganism Enterobacter sakazakii (E. sakazakii) has been found to be a serious health hazard to 
newborns.  Its  presence  in  powered  infant  milk  formula  can  cause  sporadic  cases  of  meningitis  and 
necrotizing enterocolitis, an inflammatory disease of the gut. Consequently, in 2004, the FAO/WHO held 
an expert meeting to discuss the adverse health effects of E. sakazakii in powdered infant milk formula
[1].  
This study aims to investigate parents’ willingness to pay (WTP) for safer infant milk formula with 
a  quality  assurance  label.  In  addition,  this  study  assesses  the  effect  of  provision  of  ambiguous  risk 
information and safe-handling information on parent’s WTP using experimental auctions (i.e., second 
price sealed bid auction). Our findings generally imply that parents significantly value a quality assurance 
label  with  or  without  clear  incidence  rate  information.  This  valuation,  however,  is  reduced  by  the 
provision of safe-handling information.  
The  paper  is  organised  as  follows.  Section  2  provides  background  information  on  the 
microbiological risks of powdered infant  milk  formula, the  marketing of breast-milk  substitutes, and 
briefly outlines some aspects of ambiguity. The structure and design of the experiments are described in 
section 3. Section 4 presents and discusses the results focusing on the WTP measures, tests for ambiguity, 
and the effect of safe-handling information. The paper concludes in section 5.  
 
 
 2 Background  
 
We aim to link the health risk associated with contaminated infant milk formula to the measurement 
of WTP for a quality assurance label indicating a safer product. In this section, we start with briefly 
discussing the health risks and the debate about marketing of breast-milk substitutes. We then describe 
the issue of ambiguity. 
   2 
2.1 Microbial risks of powdered infant milk formula 
 
According to the current WHO feeding recommendations for developed countries, newborns should 
exclusively be breastfed within the first 4 to 6 month of their life 
[2]. Breast-feeding is the best and most 
natural way to nourish a baby. It is valuable in a nutritional context because breast milk provides the 
adequate  content  of  nutrients  to  meet  the  newborns’  requirements  for  growth  and  development
[3]. 
Epidemiologic  evidence  suggests  that  breastfeeding  protects  infants  against  several  diseases  such  as 
gastrointestinal and respiratory infection
[2]. In cases when mothers cannot or do not want to breast-feed 
their children, a wide range of powdered infant milk formulas are commercially available. Powdered 
infant milk formulas, however, cannot be produced and packed sterile. It can contain low numbers of 
microorganisms, such as Enterobacter sakazakii (E. sakazakii), that can lead to foodborne diseases and 
serious health hazard to infants. E. sakazakii has a ubiquitous character. It is difficult to control because it 
is widespread and can be found in all environments. There is currently still a lack of knowledge regarding 
many aspects of E. sakazakii. More research is needed on its dose/response relationship in humans, the 
specific virulence mechanism, and the sources and vehicle of infection
[4]. E. sakazakii has been found in 
various types of food, but only powdered infant milk formula has been linked to outbreaks of infection
[5].  
The occurrence of this pathogen in infant milk formula is especially dangerous for premature infants 
and newborns  with low birth  weight (≤ 2,000 g). Immuno-compromised infants and those  who are 
medically debilitated are more likely to be susceptible to infections. E. sakazakii can cause neonatal 
sepsis, bacterial meningitis, and neonatal necrotizing enterocolitis, an inflammatory disease of the gut that 
can lead to death. The mortality rate for meningitis is 20 to 50 %. Children who survive often suffer from 
severe neurological disorders
[1,5]. Between 1961 and 2003, 48 cases of E. sakazakii induced infections 
among infants were reported. According to the U.S. FoodNet 2002 survey, the infection rate with this 
pathogen in infants under 1 year of age is 1 per 100,000 infants. Among low-birth-weight newborns, 
however, the infection rate is 8.7 per 100,000. Consequently, not the frequency but the severity of the 
disease  is  a  matter  of  concern
[5].  The  WHO,  however,  states  that  there  might  be  a  significant 
underreporting of this disease in all countries
[6]. Adults with infections have milder outcomes whereas the 
elderly like the very young are particularly at risk
[5, 7].  
 
 
2.2 Marketing of breast-milk substitutes 
 
Powdered infant milk formula is not just a food. It is a substitute for a natural product. Even if breast 
milk is today regarded as being superior to breast-milk substitutes, it is not always possible to breast-feed 
a baby. Mothers have biological, social, or economic reasons why they decide or have to decide not to 
breast-feed (e.g., have to take medical drugs, have physical problems, have or want to go back to work). 
The efforts of companies to increase the demand for breast-milk substitutes led to the “International Code 
of Marketing of Breast-milk Substitutes” adopted on May 21, 1981
[8]. The code has been controversially 
discussed before and after its implementation. See Greer (1990) for a more detailed discussion on the pros 
and cons. The code’s aim was to provide infants with safe and adequate nutrition 
[9]. If it is necessary to 
feed breast-milk substitutes, they should be used properly by giving adequate information and through 
appropriate marketing and distribution. From its inception, the code defined and regulated many aspects 
of the marketing of breast-milk substitutes, e.g. its definition “[…] any food being marketed or otherwise 
presented as a partial or total replacement for breast milk, whether or not suitable for that purpose” (
[10], p. 
8). The  Code  also requires  that  the  words  "Important  Notice"  or  their  equivalent  have  to  be on  the 
packaging as well as the statement of the superiority of breastfeeding, a statement that the product should 
be used only on the advice of a health worker as to the need for its use and the proper method of use, 
instructions  for  appropriate  preparation,  and  a  warning  against  the  health  hazards  of  inappropriate 
preparation
[10]. It is, however, not specified that the product is not sterile. Hence, there is no assurance that 
the product contains no pathogens that can cause adverse health effects. A quality assurance label could 
help provide additional information to overcome this information asymmetry. It could also signify that 
powdered infant milk formulas are not sterile and the labeled product is relatively safer compared to 
others. This would enable the consumer or the purchaser, respectively, to make an informed decision 
when purchasing powdered infant milk formula. 
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2.3 Ambiguity in communicating health risk information 
 
Two dimensions are usually considered to determine a choice situation. The first one is the relative 
desirability of the possible pay-off, and the other one is the likelihood of the events that are affecting 
them. The third factor that could be added is the information somebody has about the relative likelihood 
of  events
[11].  The  ambiguity  of  this  information  is  “[…]  a  quality  depending  on  the  amount,  type, 
reliability and “unanimity” of information, and gives rise to one’s degree of “confidence” in an estimate 
of  relative  likelihoods”  (
[11],  p.  657).  Camerer  and  Weber  (1992)  applied  the  following  definition  of 
ambiguity: “Ambiguity is uncertainty about probability, created by missing information that is relevant 
and could be known” (
[12], p. 330).  
Fox and Tversky (1995) argued that when people compare two events with having different levels of 
knowledge about them, then the less familiar bet is less attractive compared to the more familiar one. This 
is called the comparative ignorance hypothesis. That is, ambiguity aversion is assumed to be present when 
subjects evaluate clear and vague prospects jointly (within-subject design), but diminishes or disappears 
when the prospects are evaluated in isolation (between-subject design). The hypothesis predicts that the 
clear bet will be priced above the vague bet. This discrepancy is likely to be more pronounced when clear 
and vague bets are traded jointly than separately
[13]. For example, Chow and Sarin (2001) showed in their 
experiments  that  the  clear  bet  is  priced  higher  than  the  vague  bet  under  both  comparative  and  non-
comparative conditions 
[14]. In our study, we hypothesize that ambiguity in risk information influences 
WTP. The ambiguity is represented by the unclear incidence rate (i.e., unclear probability of occurrence 
of an E. sakazakii infection). The next section discusses the experimental design and treatments used to 
test ambiguity and safe-handling information effects. 
 
 
3 Experimental design 
 
In November and December 2005, 84 mothers and fathers participated in our experiments using 
Vickrey auction in a member state of the European Union (i.e., Germany). Participants were randomly 
recruited either through flyer or personal communication. We were seeking parents who feed/ fed their 
newborns  powdered  infant  milk  formula  and  are  responsible  for  purchasing  the  formula.  During  the 
recruitment,  the  participants  were  not  provided  information  about  the  details  of  the  study  to  avoid 
participation bias related to food safety aspects of powdered infant  milk  formula. The subjects  were 
randomly  assigned  to  one  of  three  treatments  discussed  below.  We  conducted  a  total  of  eight 
experimental auction sessions with group sizes ranging from 6 to 14 participants. Prior to the actual 
experimental auction sessions, the respondents were asked to fill in an entry questionnaire containing 
questions about the milk formula they feed, information sources that they use concerning baby food, 
reasons for not breastfeeding, socio-economic questions and others.  
 
 
3.1 Design to test ambiguity effects 
 
The experiment was programmed and conducted with the software z-Tree 
[15] and involved three 
treatments. The first two treatments were designed to test between-sample ambiguity effects while the 
third treatment was designed to test within-sample ambiguity effects. 
In Treatment 1, the participants received information about the pathogen but were not provided clear 
information about the incidence rate (called “Unclear” treatment). The information about the pathogen 
included  information  on  the  microorganism  E.  sakazakii,  the  diseases,  symptoms  and  adverse  health 
effects it might cause, the population at risk, and the possibility that it can be found in powdered infant 
milk formula. In treatment 2, the participants also received the same information about the pathogen but 
unlike Treatment 1, they received clear or unambiguous information about the incidence rate (called 
“Clear” treatment). The unambiguous incidence rate mentioned was one child out of 100,000 under 1 year 
of age. Participants were thus asked to avoid a risk with known outcome (i.e. the symptoms) but known or 
unknown  likelihood  of  occurrence  (i.e.  the  incidence  rate),  respectively.  The  auctions  for  these  two 
treatments to test between-sample ambiguity effects involved 5 trials each. Treatment 3 (called “Both” 
treatment) (see Table 1), designed to test within-sample ambiguity effects, involved two sets of 5 trials 
each.  In  the  first  set  of  trials,  the  clear  or  unambiguous  incidence  rate  was  not  mentioned  to  the 
participants while in the second set of trials, the participants were informed of the unambiguous incidence   4 
rate. The participants were asked to bid for an infant milk formula with a quality assurance label that the 
producers intend to introduce. The label signifies the absence of the pathogen E. sakazakii and hence, the 
assurance of safety
1. Then they bid for the certified milk formula and stated how much they are willing to 
pay more than 1.15 Euro (served as basic price level) per 100 grams. The auctions involved 5 trials or 
rounds of bids so that participants could incorporate market feedback into their valuations. Subjects were 
told that only one round would be randomly selected to be binding, to control for demand reduction or 
wealth effects, and that the winner would be the individual with the highest bid, with the winning auction 
price being the second highest price. Before the actual experiments, a coffee mug auction was conducted 
to  familiarize  the  participants  with  the  Vickrey  auction  procedure.  The  questionnaires  and  the 
experimental instructions are available from the corresponding author upon request. The participants were 
aware of the fact that the auction was hypothetical and that they would not really have to buy the milk 
formula. We chose the hypothetical approach for several reasons. It would not have been possible to 
guarantee that the purchased milk formula is free of E. sakazakii nor would it been ethically to provide 
parents with an “unsafe” milk formula and ask them to change it against a “safe” one.  
 
 
Table 1. Structure of the lab experiment 


































































































































2 Not applied 
 
 
3.2 Design to test safe-handling information effects 
 
After the trials conducted to test ambiguity effects, the participants in all three treatments were given 
information on the preparation techniques that would enable them to control for the health risk. The risk 
of an infection of E. sakazakii can be decreased by several preparation techniques that parents apply when 
they reconstitute the milk powder. This knowledge puts parents in the position to self-control the health 
risk to their newborns. It is recommended, for example, that powdered infant milk formula should be 
prepared fresh immediately before the feeding, remnants should be discarded, reconstituted milk formula 
should not be kept warm in bottle heaters, and if the storage of prepared formula is necessary, the formula 
                                                 
1 We did not show the participants a real label. The label and its meaning were just described to them. 
This was done to avoid biasing the results due to possible differences in participants’ views about whether 
or not they like how the label was designed. 
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should be kept at 4°C for not more than 30 hours
[16]. This information about preparation techniques to 
reduce infection from E. sakazakii is used in this study to evaluate the effect of health risk reduction 
information  on  WTP  values.  The  wordings  of  the  preparation/safe-handling  techniques  used  in  the 
experiment are exhibited in Figure 1. After the participants received this information, they then proceeded 
with another set of five trials of the experiment
2. A summary diagram of the experiments is exhibited in 
Table 1.   
After all the trials, the participants filled in an exit questionnaire which included questions related to 
their support of the introduction of the label (see Table 2), their assessment of the risk that their child will 
get sick due to E. sakazakii, and the importance of risk reduction . Each participant then received a 
participation  remittance  of  20  Euro  in  cash.  Additionally,  we  distributed  a  leaflet  that  summarized 
information on the “actual” situation of the E. sakazakii problem and the latest scientific findings. We 
also informed the participants of the internet address of the state authority that conducts risk assessment 
and offers information on this particular issue. The results of the lab experiment are described in detail in 




If there are pathogens of the species Enterobacter sakazakii present in the not labelled powdered infant 
milk formula an increase of the germs can be prevented by following some guidelines for the handling 
and storage of reconstituted infant milk formula. It is recommended to consider the following preparation 
techniques: 
 
•  Clean the bottle and the teat properly before using them.   
 
•  Use boiled water.  
 
•  Cool down the reconstituted milk formula immediately to drinking temperature and feed it. 
 
•  Powdered infant milk formula should be prepared freshly immediately before the feeding. It 
should not be stored for the whole day. 
 
•  Avoid keeping reconstituted milk formula warm in bottle heaters. 
 
•  If storage of prepared formula is necessary, the formula should be cooled down to 4°C and kept 
at his temperature. 
 
•  Remnants should be discarded and not fed later. 
 
 









                                                 
2 Despite the sensitiveness of the topic, we had no incidents of emotional panic or similar reactions in our 
experiments. All subjects finished the experiments and had the opportunity to ask questions afterwards. 
Technical questions or questions about the understanding of the procedure could be asked any time during 
the experiment but communication between the participants was not allowed.      6 
Table 2. Selected sample characteristics 







Male  7  8.3 
 





  31.75/4.41  29.00/32.00/35.00 
 
Household Monthly Net Income
1 
   
< 920 Euro   2  2.4 
920-1.500 Euro  7  8.3 
1.501-2.500 Euro   41  48.8 
2.501-3.500 Euro   24  28.6 
3.501-4.500 Euro   6  7.1 
4.501-6.500 Euro   2  2.4 
6.501-8.500 Euro   1  1.2 
8.501-10.500 Euro   0  0 
10.501-12.500 Euro   0  0 
>12.500 Euro   1  1.2 
     
Household Size  Mean/Std. dev.  Percentile (25/50/75) 
  3.60/0.95  3/3/4 
     
Price versus Food Safety
2  Mean/Std. dev.  Percentile (25/50/75) 
  6.07/1.00  5/6/7 
 
 
Do you support the introduction of the label? 
   
No, not at all  1  1.2 
No  4  4.9 
Partly  20  24.4 
Yes  39  47.6 
Strongly yes  18  22.0 
     
 
Notes: 
1 The income was expressed in numbers from 1 to 10 corresponding to the income category. 
2 The 
respondents were asked to indicate their preference on a scale from 1 to 7 where 1 meant “low price over 
all” and 7 “highest food safety over all”. 
 
 
4 Results and discussion 
 
The subjects answered several questions about their reasons for not breast-feeding, their purchasing 
patterns, the use of information sources, their socio-demographic characteristics, etc. Selected sample 
characteristics  are  summarized  in  Table  2.  Mainly  mothers  participated  in  the  survey  (91.7%).  The 
participants were aged between 21 and 41. The mean age is 31.75 years. The households have an average 





The elicited WTP amounts are summarized in Table 3. Average bid figures are for the last trials 
(i.e., 5
th trial). Different bid levels are found in the different treatments. In treatment 1, we elicited a mean   7 
WTP of 91 Eurocents before the safe-handling information was given and an amount of 66 Eurocents 








1Unclear  means  that  the  unambiguous  incidence  rate  is  not  provided/ 
2Clear  means  that  the 
unambiguous  incidence  rate  is  provided/ 
3Both  means  that  the  unambiguous  incidence  rate  is  not 
mentioned  before  the  first  5  trials  are  made  and  is  then  mentioned  before  the  next  5  trials  follow/ 
4Average without zero bids in parenthesis. 
 
 
The  bids  in  treatment  2,  when  the  participants  were  provided  unambiguous  incidence  rate 
information,  are  generally  lower  than  the  bids  in  treatment  1,  when  participants  were  not  provided 
unambiguous incidence rate information. In treatment 2, the mean WTP is 61 Eurocents before provision 
of safe-handling information and 39 Eurocents after the provision of safe-handling information. 
The  bids  in  the  “Both”  treatment  (treatment  3)  are  higher  than  in  the  other  two  treatments. 
Specifically,  we  obtained  a  mean  WTP  of  129  Eurocents  per  100  grams  before  the  unambiguous 
incidence rate was mentioned (i.e., first set of 5 trials) and 133 Eurocents after they were informed of the 
unambiguous incidence rate (i.e., second set of 5 trials).  
In our experiment, we asked the participants to state their WTP for a labelled product that is not 
consumed by them but by their children. In the exit questionnaire, we told the participants to imagine if 
their own health would have been the matter of concern, not their children. We wanted to know if they 
would have bid more, equally or less. Interestingly, 47% of the respondents indicated that they would 
have stated a lower WTP, 51.8% answered they would have bid the same amount, and only 1.2% said that 
they  would  have  paid  more.  In  a  related  study  by  Dickie  and  Messman  (2004),  a  stated  preference 
approach was used to evaluate parents’ preferences to ease symptoms of acute illnesses for their own and 
their children. It was found that parents value illness attributes of their children twice as highly as their 
own. This effect was more pronounced for younger children. These results were interpreted to reflect 
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(After providing information on 
preparation techniques to decrease 






Unclear  BothClear  Unclear  Clear  Both
 
 
Auction, Trial 5: 
 




4  61 (69)  129 (138)
  133 (138)  66 (71)  39 (48)  69 (89) 
Median bid 
 
65  50  93  85  50  40  60 
Second- highest bid 
 
200  150  350  351  150  115  185 
Standard deviation  
 
70.59  50.82  112.78  123.31  55.32  34.87  69.39 
No. of zero bids 
 
1  3  2  1  2  5  7 
No. of respondents  26  27  31  31  26  27  31 
                 8 
Since almost half of the survey population in our study would have behaved differently if they were 
personally affected, we suggest that altruism plays a role in WTP valuations. 
 
 
4.2 Testing for the ambiguity effect 
 
The statistical tests conducted to examine the ambiguity effects are presented in Table 4. The first 
test we conducted was to examine the null hypothesis in treatment 3 that the bid distribution in the 5
th trial 
between  the  group  given  the  unambiguous  incidence  rate  and  the  group  that  was  not  given  the 
unambiguous incidence rate is identical using Wilcoxon’s signed-rank test. The test result indicates that 
there is no difference statistically (p=0.436). Hence, we found no significant ambiguity effects in the 
within-sample design of the experiment. This result is confirmed by the summary statistics in Table 3 as 
well. Clearly, the information about the unambiguous incidence rate did not significantly affect the level 
of the bids in treatment 3. However, comparing the fifth trial before the unambiguous incidence rate was 
mentioned and the first trial after the unambiguous incidence rate was mentioned, the difference between 
the  mean  WTP  is  statistically  different  at  the  5%  level  (p=0.013).  The  unambiguous  incidence  rate 
information clearly decreased the mean WTP significantly from 129 to 87 Eurocents (see Figure 2). This 
can  be  interpreted  as  being  an  ambiguity  effect  since  the  new  information  about  the  unambiguous 
incidence rate significantly diminished the WTP in the trial right after the unambiguous information was 


















































Without incidence rate With incidence rate Safe-handling information  
Figure 2. Comparison of trials for the different treatments 
 
Using the Kolmogorov-Smirnov two-sample test, we tested the null hypothesis that the population 
distributions of the bids between the different treatments are identical. We tested if treatment 1 bids differ 
from  treatment  3  bids  before  provision  of  the  unambiguous  incidence  rate  information.  The  null 
hypothesis cannot be rejected (p=0.303) suggesting that we could not find ambiguity effects between the 
two treatments. We also tested if treatment 2 bids differ from treatment 3 bids after the provision of the 
unambiguous incidence rate information. The null hypothesis of this test also cannot be rejected.    9 
Using the last trials, the distribution of the bids in treatment 1 was compared with the distribution of 
the bids in treatment 2. We could not find an ambiguity effect either between the treatments (p=0.292). In 
summary, no ambiguity effects were generally found in our experiments either from the within-sample 
treatment (treatment 3) or from the between-sample treatments (treatments 1 and 2). The only exception 
is when comparing the last trial before the provision of the unambiguous incidence rate information and 
the first trial after the provision of the unambiguous incidence rate information in treatment 3. It is not 
clear why ambiguity in incidence rate information does not generally have a significant effect on WTP. 
However, it is possible that parents do not care about the clearness or ambiguity of incidence rate because 
this is in regard to the health of their child. This is consistent with Kahneman and Tversky’s (1979) 
finding that people tend to be risk-averse when they are faced with a small chance of losing a large 




4.3 Testing for the effect of safe-handling information 
 
We  hypothesized  that  the  safe-handling  information  we  provided  decreases  the  WTP  because 
parents can then self-control the health risk. To investigate this, we tested the null hypothesis that the 
population distributions within each treatment are identical using Wilcoxon’s signed-rank test. We used 
the last trial of the different treatments for the test. In all the three treatments, the effect of the information 
was found to be statistically significant (see Table 4). In treatment 1, the WTP reduction is statistically 
significant at the 5% level while in treatments 2 and 3, the decrease in WTP is statistically significant at 
the  1%  level.  Hence,  information  on  the  preparation  techniques  significantly  reduced  participants’ 
valuation of the label (also see Figure 2). 
In  summary,  the  key  finding  that  emerges  from  our  experiment  is  the  significant  effect  of  the 
provision  of  safe-handling  information.  Providing  information  to  the  participants  on  the  preparation 
techniques that helps to decrease the health risk influences the WTP and leads to a significant decrease in 
WTP, as expected. Interestingly, the WTP did not decline to zero with the provision of the safe-handling 
information. It is, however noteworthy that we had five zero bids in treatment 2 and seven zero bids in 
treatment 3 when the information on the preparation techniques was provided. These results may suggest 
that the information on the unambiguous incidence rate made it easier for the respondents to calculate the 






This study assessed parents’ WTP for quality assurance labelled powdered infant milk formula. 
Using experimental auctions, our results indicate that the mean price premiums parents were willing to 
pay ranges from 61 to 133 Eurocents,  given a basic price level of 115 Eurocents per 100 grams of 
powdered infant milk formula. This result means that parents are willing to pay price premiums from 53% 
to 116% of the base price per 100 grams. Our experiments also examined if ambiguous information about 
health risk (i.e., incidence rate) as well as information about safe-preparation techniques affect WTP. Our 
results generally suggest no significant ambiguity effects but substantial safe-handling information effects 
on  WTP.  The  WTP  declined  by  39  to  69  Eurocents  after  the  provision  of  information  about  the 
preparation techniques. This finding suggests that our subjects attached a lot of importance to safe food 
handling techniques that could reduce the health risk. 
Our findings imply that parents indeed significantly value a quality assurance label with or without 
clear incidence rate information. Parents’ valuation of this label, however, is reduced with the provision 
of safe-handling information. It may then be prudent for the infant milk formula industry to provide both 
a quality assurance label and the information on safe-handling preparation techniques. Future studies 
should, however, replicate our study to assess the robustness of our findings in other countries. Analyzing 
the welfare effects of our findings is also warranted given data availability.   10





1Superscript = treatment, Subscript = trial, ***Significance level = 0.01/ ** Significance level = 
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